IP Library Granted Patent US 8,895,243
Granted Patent B2
US 8,895,243 · App. 13/686,128 · Granted Nov 25, 2014

Method of assessing cancerous conditions and reagent for detecting gene product to be used in the method

Inventors: Masato Maekawa (Hamamatsu, JP); Takeshi Uramoto (Ryugasaki, JP)
Assignee: Sekisui Medical Co., Ltd.
C12Q1/6886G01N33/574
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,243
App. No.
13/686,128
Granted
Nov 25, 2014
Kind
B2
Abstract

A reagent for detecting gene product, the reagent comprising a probe or chemical modulation that specifically binds to an alternative splicing junction of a gene product of human PTCH1 gene, the expression of the gene product from gene products of the human PTCH1 gene being varied due to the unusual alternative splicing, for use for measuring the abundance of the gene product contained in a human sample.

Claims (9)

1. A method of determining a colon cancer tissue in a human test patient comprising:

obtaining a first sample from a non-cancerous human subject and a second sample from the test patient,

measuring a transcription product of the human patched homolog 1 (PTCH1) gene comprising SEQ ID NO: 1 in the first and second sample by contacting the samples with a probe or primer that hybridizes to the splice junction in SEQ ID NO: 1 or the complement of SEQ ID NO: 1, wherein the splice junction is between exon1B and exon 3 of PTCH1, and

comparing the level of measured transcription product from the first and second samples, wherein if the level of measured transcription product in the second sample is higher than the level of measured transcription product in the first sample, the test patient comprises a colon cancer tissue.

2. The method according to claim 1 , wherein the probe or primer hybridizes to the complement of SEQ ID NO: 1.

3. The method according to claim 1 , wherein the first sample, the second sample, or both is a tissue sample.

4. The method according to claim 1 , wherein the method of measuring is any one of the measuring methods selected from the group consisting of a micro-array method, an RT-PCR method, a real time PCR method, a subtraction method, a differential display method, a differential hybridization method, and a cross hybridization method.

5. The method according to claim 2 , wherein the probe or primer is 15 to 30 nucleotides long.

6. The method according to claim 1 , wherein the probe or primer is 15 to 30 nucleotides long.

Assignments (1)
CHANGE OF NAME Recorded Dec 18, 2012
From: DAIICHI PURE CHEMICALS CO., LTD.
To: SEKISUI MEDICAL CO. LTD.
Reel/Frame 029490/0419 →
Priority Claims (1)
JP 2004-366206 · Dec 17, 2004 · national
Continuity (2)
Division 11722007
Related Publication 20130172200A1 · Jul 4, 2013